Vikas Lifecare Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
VIKASLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.3 pts less than Nifty Microcap 250 and 0.1 pts less than its Trading & Distributors peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Vikas Lifecare's board approved unaudited standalone and consolidated results for the quarter and half year ended September 30, 2025, and the quarter and nine months ended December 31, 2025. For H1 FY26 (standalone), revenue from operations rose modestly to ₹22,966.97 lakhs (vs ₹22,191.81 lakhs in H1 FY25), while reported net profit jumped to ₹12,414.82 lakhs driven almost entirely by a one-time ₹13,342.84 lakhs other income from the Ebix/EIHL settlement. Excluding fair-value investment changes, core H1 profit was ₹12,692.91 lakhs. Q2 FY26 standalone, however, swung to a net loss of ₹349.41 lakhs on revenue of ₹14,097.78 lakhs, with core operations remaining unprofitable. The auditor issued an unmodified review report but flagged multiple emphasis-of-matter items: the Ebix settlement and pending regulatory approvals, the restatement of Q1 FY26 results (profit revised from a ₹280 lakh loss to a ₹12,764 lakh gain), material related party transactions done without prior shareholder approval, the pending IGL Genesis Technologies share transfer, and unevaluated tax implications of the Ebix deal. The board also approved an addendum to the postal ballot to seek shareholder consent for future RPTs, investments, loans, and guarantees.
The headline profit growth is misleading — it is almost entirely from a one-time Ebix/EIHL settlement gain, while core operations posted losses in Q2 FY26. The restatement of Q1 results and material RPTs executed without shareholder approval are governance red flags that may attract regulatory scrutiny. Pending tax assessments and regulatory approvals for the EIHL acquisition introduce uncertainty; investors should focus on underlying operating performance rather than the inflated reported profit.